Food and Drug
Administration
Peripheral and Central Nervous System Drugs Advisory
Committee
May 17, 2006
Briefing Information
Novartis Pharmaceutical Corp.
Disclaimer
The statements contained in this document(s) are those of the product's
sponsor, not FDA, and FDA does not necessarily agree with
the sponsor's statements. FDA has not made a final determination
about the safety or effectiveness of the product described
in this document.
NDA 20-823; SE1-016 Exelon ® (rivastigmine
tartrate) capsules (
pdf)
FDA
Disclaimer
Portions of this document have been determined
to be exempt from disclosure under the Freedom of Information
Act (the FOIA) (5 U.S.C. §552).
These redacted portions will appear as white space on the
screen or on the printed page.
Briefing Information
Tab 1.
Background Document (pdf)
Tab 2.
FDA Clinical Review (pdf)
Tab
3. Statistical Review (pdf)
Bibliography
(htm)